Avraham Biger - Rekah Pharmaceutical Chairman of the Board
| REKA Stock | ILA 1,280 60.00 4.48% |
Chairman
Mr. Avraham Biger was appointed Chairman of the Board at Rekah Pharmaceutical Industry Ltd. effective April 15, 2015. His work experience includes the following roles Chairman of the Board at Machteshim Agan Industries Ltd between 2007 and 2010, Chief Executive Officer at Machteshim Agan Industries Ltd between 2007 and 2009 and Director at El Al Israel Airlines Ltd between 2011 and 2013 since 2015.
| Age | 71 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 972 3 558 1233 |
| Web | https://www.rekah.co.il |
Rekah Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0222 %, meaning that it generated $0.0222 on every $100 dollars invested by stockholders. Rekah Pharmaceutical's management efficiency ratios could be used to measure how well Rekah Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | CHAIRMAN Age | ||
| Martin Gerstel | Compugen | 72 | |
| Joseph Rauch | Bonus Biogroup | 54 | |
| Yosef Rauch | Bonus Biogroup | 58 | |
| Paul Sekhri | Compugen | 61 | |
Management Performance
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 |
Rekah Pharmaceutical Leadership Team
Elected by the shareholders, the Rekah Pharmaceutical's board of directors comprises two types of representatives: Rekah Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rekah. The board's role is to monitor Rekah Pharmaceutical's management team and ensure that shareholders' interests are well served. Rekah Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rekah Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amiram Boehm, Director | ||
| Michael Avnimelech, External Director | ||
| Chaim Cohen, Chief Officer | ||
| Yaakov Elgrabli, Chief Ltd | ||
| Ilan Horesh, External Director | ||
| Arye Elgrably, CEO, Director | ||
| Yuval Bernshtein, Vice President - Finance | ||
| Haim Cohen, CFO | ||
| Orly Zilberman, External Director | ||
| Meir Melumad, Director Operations | ||
| Avraham Biger, Chairman of the Board | ||
| Mordechai Elgrabli, CEO Director | ||
| Yuval Elgrably, Deputy CEO | ||
| Yuval CPA, Chief Officer | ||
| Ronit Zelnik, Head of Projects Division | ||
| Jack Azran, Chief Technologies | ||
| Georgette Elgrabli, Director Director | ||
| Ehood Nisan, External Director | ||
| Ishay Davidi, Director | ||
| Yuval Elgrabli, Deputy Devel | ||
| Jacob Elgrably, Chief Shalpharm | ||
| Arnon Zuaretz, External Director | ||
| Menachem Dasberg, Vice President-Economic Division Manager | ||
| Georgette Elgrably, Head of Industrial Division, Director | ||
| Snir David, Vice President - Finance |
Rekah Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rekah Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Shares Owned By Insiders | 37.27 % | |||
| Shares Owned By Institutions | 42.66 % | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rekah Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rekah Pharmaceutical's short interest history, or implied volatility extrapolated from Rekah Pharmaceutical options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rekah Pharmaceutical Industry. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |